July 17, 2018
Bookmark and Share

Captozyme Initiates Clinical Study of Nephure™ Oxalate-Reducing Enzyme

GAINESVILLE, Fla. , July 11 /Businesswire/ - Captozyme, Inc. announced today that it is initiating a prospective double-blind, randomized, placebo controlled, cross-over study, with Nephure™, an oxalate reducing enzyme.


STORY TAGS: Seniors, Women, United States, North America, Health, Biotechnology, Clinical Trials, Florida, Other Health, Research, Other Science, Consumer, Science, Men,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News